Literature DB >> 2552129

Distribution and function of human ventricular beta adrenergic receptors in congestive heart failure.

A R Denniss1, W S Colucci, P D Allen, J D Marsh.   

Abstract

This study examined the characteristics and distribution of sarcolemmal and light vesicular beta-adrenergic receptors (BAR) in left ventricular myocardium from 15 adults (aged 17 to 58 years) without left ventricular dysfunction or coronary artery disease and 29 patients (aged 14 to 53 years) with end-stage congestive heart failure (CHF). Sarcolemmal and intracellular fractions were prepared by 40,000 x g and 108,000 x g centrifugation, respectively. Agonist and antagonist binding properties were assessed by nonlinear computer modelling of isoproterenol-125I-pindolol (IPIN) displacement curves. Adenylate cyclase activity was also examined. Distribution of intracellular and sarcolemmal BAR was similar in normal and failing left ventricular myocardium, with intracellular BAR comprising 4.5 +/- 2.2% of total BAR in normal human heart and 5.7 +/- 5.1% of total BAR in CHF patients. For sarcolemmal BAR, antagonist affinity was similar for normal and CHF patients (KD IPIN in normals, 21.7 +/- 2.6 pM; KD IPIN in CHF, 20 +/- 2.3 pM). Agonist affinity was somewhat higher in CHF patients (KD isoproterenol in normals, 33 +/- 4.9 nM; KD isoproterenol in CHF, 6.2 +/- 1.5 nM). Sarcolemmal BAR number was reduced in CHF from 21.4 +/- 2.9 to 16.4 +/- 1.3 fmol/mg protein (P less than 0.04). Cyclic AMP production (pmol/mg protein/min above basal) was less in CHF after Gpp(NH)p stimulation (normals, 82 +/- 20; CHF, 27 +/- 9; P less than 0.01) and after stimulation with Gpp(NH)p + isoproterenol (normals, 129 +/- 25; CHF, 56 +/- 13; P less than 0.02). Stimulation with manganese + forskolin resulted in similar levels of cyclic AMP production in normals and in CHF patients. We conclude that: (a) sarcolemmal BAR number is reduced in CHF, but BAR are not redistributed intracellularly and (b) beta-adrenergic transmembrane signalling in CHF is also impaired at the level of the guanine nucleotide regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552129     DOI: 10.1016/0022-2828(89)90606-8

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.

Authors:  M Shahid; M G Martorana; J E Cottney; R J Marshall
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

Review 2.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

3.  Beta-adrenoceptors in human alveolar macrophages isolated by elutriation.

Authors:  P Hjemdahl; K Larsson; M C Johansson; A Zetterlund; A Eklund
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 4.  Beta-adrenergic receptors in failing human myocardium.

Authors:  O E Brodde
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

5.  Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure.

Authors:  T Takahashi; P D Allen; R V Lacro; A R Marks; A R Dennis; F J Schoen; W Grossman; J D Marsh; S Izumo
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Down-regulated beta-adrenoceptors in severely failing human ventricles: uniform regional distribution, but no increased internalization.

Authors:  H F Pitschner; A Droege; M Mitze; M Schlepper; O E Brodde
Journal:  Basic Res Cardiol       Date:  1993 Mar-Apr       Impact factor: 17.165

Review 7.  Changes in adrenergic receptors during the development of heart failure.

Authors:  N S Dhalla; I M Dixon; S Suzuki; M Kaneko; A Kobayashi; R E Beamish
Journal:  Mol Cell Biochem       Date:  1992-09-08       Impact factor: 3.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.